Trial Profile
Phase II Study of the Safety and Efficacy of Allovectin-7 Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 May 2014
Price :
$35
*
At a glance
- Drugs Velimogene aliplasmid (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vical
- 03 May 2014 New trial record